Abid Mallick, MD
Cardiovascular Disease · Wichita, KSNPI 1538116488
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,199 of the $1,690 with a category attached, or 70.9%. Medtronic accounts for 77.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $625 and has fallen 74.2% since, to $161 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in KS, where the typical reported total is $2,383.
Across 41 payments — averaging $41.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- AstraZeneca$161
- Pfizer$39
- Novartis$38
- Cvrx, Inc.$26
- Novo Nordisk$25
- plus $85 from 5 others
Across 4 payments — averaging $1777.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim International GmbH$431
What the payments were for
- Travel & lodging$49129%
- Food & beverage$1,19971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 27 | $1,317 |
| AstraZeneca | 1 | $161 |
| Pfizer | 3 | $39 |
| Novartis | 2 | $38 |
| Cvrx, Inc. | 2 | $26 |
| Novo Nordisk | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Surmodics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,690 in reported general payments places this provider in the 40th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 358 | $305,146 |
| EntrestoSacubitril/Valsartan | 201 | $190,886 |
| XareltoRivaroxaban | 138 | $142,436 |
| Repatha SureclickEvolocumab | 119 | $104,448 |
| Praluent PenAlirocumab | 60 | $65,536 |
| JardianceEmpagliflozin | 11 | $11,391 |
| Bumetanide | 175 | $4,257 |
| Potassium Chloride | 269 | $4,208 |
| Flecainide Acetate | 107 | $3,374 |
| ClopidogrelClopidogrel Bisulfate | 366 | $2,446 |
| Carvedilol | 280 | $2,367 |
| Nifedipine ErNifedipine | 79 | $2,311 |
| Metoprolol Succinate | 178 | $2,145 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 155 | $1,748 |
| Losartan Potassium | 253 | $1,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $39 | $305,146358 claims |
| NovartisEntresto | $38 | $190,886201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$482K
- Joseph GalichiaWichita$177K
- Wassim ShaheenWichita$137K
- Layne ReusserWichita$91K
- Aziz MaksoudWichita$81K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.